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ABSTRACT: To find novel P-gp-inhibitors, a library of pregnane X receptor (PXR) ligands and the ZINC DrugsNow library were 
superimposed on the P-gp inhibitor (+)-pinoresinol (1) used as a query for a 3D similarity search. After determining the 
TanimotoCombo index of similarity with 1, eight compounds from the PXR library and two ZINC compounds were selected for 
biological evaluation. The P-gp inhibition study showed that compounds 7, 8 and 9 successfully increased intracellular doxorubicin 
(DOX) accumulation in the P-gp overexpressed Lucena 1 cells from 25, 12.5 and 6.25 μM, respectively. Among a series of analogs 
of 9, compounds 26-30 were shown to be active, with 26 and 27 causing a significant increase in DOX accumulation from 1.56 µM 
and rendering Lucena 1 sensitive to DOX from 1.56 and 0.78 µM, respectively. Molecular modeling studies showed that both 
compounds bind to the P-gp at transmembrane helices (TMH) 4, 5 and 6, with 27 also showing contacts with TMH 3.
The development of drug resistance in cancer cells is a major 
barrier to successful chemotherapy. Among the various 
mechanisms behind multidrug resistance (MDR),1 the increased 
energy-dependent efflux of a broad set of structurally unrelated 
cytostatic drugs is one of the most commonly encountered.2 
This phenomenon is mediated by transport proteins3, the best 
characterized of which is P-glycoprotein (P-gp) encoded by the 
mdr-1 gene, one of the 49 identified ATP-binding cassette 
(ABC) transporters.4 P-gp contains two transmembrane 
domains, each consisting of six transmembrane α-helices 
(TMHs) and a nucleotide-binding domain (NBD).5 The latter 
hydrolyzes ATP to drive the transport of the binding substrate. 
The importance of P-gp is that it is expressed in almost half of 
human tumors2, being observed in many types of leukemia,2 
including chronic myelogenous leukemia.6 
Despite some encouraging results,7 most of the P-gp 
inhibitors submitted to clinical trials were disappointing, mainly 
due to their side effects, interactions with co-administered 
drugs, or defects in the experimental design.8, 9 The 
development of drugs able to counteract the resistance mediated 
by P-gp is thus imperative. Natural compounds have attracted 
great attention and are considered fourth generation P-gp 
inhibitors.9 A preceding paper reported that the lignan (±)-
pinoresinol, isolated from Melia azedarach,10 showed 
inhibitory activity on the transport of doxorubicin (DOX) out of 
P-gp overexpressed chronic myelogenous leukemia cells, 
Lucena 1 from 56 μM, as demonstrated by an accumulation 
assay.2 By multidrug resistance reversal assay, (±)-pinoresinol 
was able to sensitize resistant cells to DOX from 7 μM.2 Further 
studies revealed that (±)-pinoresinol bonds to P-gp through 
residues of the TMH 4, 5 and 6, some of which are also involved 
in the binding of the reference P-gp inhibitors, verapamil and 
tariquidar.2  
This scenario and the success of plant-derived products as 
starting points for drug development11 led us to search for 
suitable candidates with improved activity compared to (±)-
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pinoresinol to specifically counteract the mechanism of drug 
resistance in cells with enhanced P-gp expression. Since the 
chemical structure of (+)-pinoresinol (1) (Figure 1) includes 
two hydroxyl groups at a distance of 1.3 nm bound to a central 
scaffold, we virtually screened our own previously synthesized 
pregnane X receptor (PXR) library (Figure 1; compounds 2-9), 
which has a similar structural feature12, 13, for similarity with 1 
using ROCS (ROCS 3.2.2.2: OpenEye Scientific Software, 
Santa Fe, NM. http://www.eyesopen.com)14. TanimotoCombo 
similarity index of shape (shape Tanimoto index) and 
pharmacophore features (color Tanimoto index) of the query 
and of compounds 2-9 was calculated. Additionally, the ZINC 
DrugsNow library, containing more than 10 million 
compounds, was also screened for three-dimensional similarity 
to 1 using the TanimotoCombo similarity index (sum of shape 
and color Tanimoto index). 
ROCS demonstrated that the identified ZINC molecules 10-
25 (Figure 1) overlay better with 1 (TanimotoCombo between 
1.413 and 1.606) than the bazedoxifene scaffold-based PXR 
antagonists 2-6 (Figure 1, TanimotoCombo between 0.717 and 
0.909) and the diethylstilbestrol scaffold-based PXR ligands 7-
9 (Figure 1, TanimotoCombo between 0.823 and 0.851) (see 
Supporting Information for representative overlays, Figure S1). 
On the basis of these results, the optimized structures of these 
compounds were studied in silico by molecular docking, using 
the human P-gp model previously built based on the 
homologous P-gp from mouse (Mus musculus) as template.15 In 
relevant cases, both stereoisomers (+/-) were investigated, and 
both OH and NH tautomers (keto and enol forms) for lactam 
compounds 20-25. As observed in Table S1, the compounds 
evaluated showed binding energies ranging from -7.07 to -9.23 
kcal/mol. To have a first estimation of the ability to reverse the 
P-gp-resistant phenotype of cancer cells, compounds 2-9, the 
most strongly binding non-tetrahydrofuran based ZINC 
compound 23 (binding energy of NH-tautomer -9.23 kcal/mol) 
and its close structural analog 21 (binding energy of OH-
tautomer -8.56 kcal/mol) were evaluated by a DOX 
accumulation assay using flow cytometry2 (see Supporting 
Information). For this purpose, the chronic myelogenous 
leukemia cells, Lucena 1,16 with 58% of the cells expressing P-
gp at the surface, were used as a model. These cells derived 
from the sensitive K562 cell line with less P-gp in the outer 
membrane (2% of cells). The retention of the cytotoxic clinical 
drug DOX, a known P-gp fluorescent substrate, inside the cells 
is commonly used to measure the capacity of a substance to 
inhibit P-gp-mediated outward transport. Efflux inhibition 
positively correlates with the intracellular concentration of the 
probe.17 The same assay was carried out in the K562 cell line 
with the aim of discarding any other synergism between the 
compounds and the fluorescent drug different from the effect on 
P-gp. 
Notably, diethylstilbestrol-based PXR ligands 7, 8 and 9 
effectively increased intracellular DOX (p < 0.05) in Lucena 1 
cells with Fluorescence Intensity Ratio (FIR) values 
corresponding to 1.06, 1.19 and 1.16, respectively, at 25 μM, 
while the bazedoxifene PXR-antagonists 2-6 and the ZINC 
compounds 21 and 23 did not enhance DOX-associated 
fluorescence (p > 0.05) (Table 1). The activity of 7-9 was not 
significantly different with respect to the activity of 25 µM of 
the well-known reference P-gp modulators verapamil, 
tamoxifen and cyclosporine A (CsA) (p > 0.05). It is worth 
noting that 7-9 did not cause a significant increase in DOX 
accumulation in the K562 cell line (p > 0.05) (Table S2) 
indicating that these compounds specifically inhibited P-gp 
transport. Taken together, the better reversal activity displayed 
by 7-9 compared to that of 2-6 and 21 and 23 would indicate 
that the diethylstilbestrol scaffold is more beneficial for 
achieving P-gp inhibitory activity than the bazedoxifene- and 
1,4,5,7-tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-one scaffold. 
Following primary screening, and with the aim of 
determining the minimum effective concentrations (MEC), 7-9 
were further tested at serial dilutions. As seen in Table 1, 
compound 7 did not restore DOX accumulation in Lucena 1 
cells at concentrations below 25 µM (p > 0.05), while 8 and 9 
turned out to be effective from 12.5 (p < 0.01) and 6.25 µM (p 
< 0.001), respectively, with no differences in activity with 
respect to verapamil, tamoxifen and CsA (p > 0.05). A dose-
dependent response was observed for 8 (b = 0.0097; p = 0.0076; 
CI 95% = 0.0043 to 0.0151) and 9 (b = 0.0090; p = 0.0496; CI 
95% = 0.00002 to 0.01797). To the best of our knowledge, this 
is the first report of the inhibition of diethylstilbestrol 7 on P-
gp-mediated transport, although inhibitory properties have been 
previously reported against the breast cancer resistance protein 
(BCRP) at 30 µM.18 In another work, 7 showed a weak 
activation (45%) of P-gp ATPase activity at 10 µM.19 Although 
mild stimulation of ATP hydrolysis may be associated with 
modulatory activity on P-gp function, as observed for the 
compound (±)-pinoresinol2 or cyclosporine A,20 no studies have 
previously been performed about the inhibitory effect of 7 on 
the P-gp-mediated efflux of drugs. Such investigations must be 
carried out based on the assumption that some molecules able 
to activate P-gp-ATPase, for instance the powerful modulator 
tariquidar21 behave as inhibitors, while others, such as DOX, 
vinblastine, progesterone or propranolol act only as 
substrates.20, 22 
The limited clinical efficacy of multiple drugs as a result of 
resistance is a complex mechanism not only attributed to the 
efflux mediated by an ABC transporter.1 It is therefore highly 
beneficial to develop multi-targeted agents for overcoming the 
resistance to pharmacotherapies.1 As well as P-gp, PXR also 
plays a key role in the MDR of cancer cells, acting as a 
xenobiotic sensor that regulates the transcription of genes that 
ultimately increase the activity of transporters and drug-
metabolizing enzymes.12, 13, 23 The dual activity of the PXR 
antagonists 7 and 9 by negatively modulating PXR activity13 
and, at the same time, the outward transport mediated by P-gp 
are is encouraging as promising agents for overcoming MDR. 
As previously reported, compound 7 was able to decrease P-
gp expression levels in MCF-7/MDR cells.24 Therefore, the 
effectiveness of this compound could be a sum of effects, 
possibly inhibiting both P-gp transport and expression. 
Given that compounds 7-9 displayed higher P-gp modulating 
activity than (±)-pinoresinol2, and aiming to optimize the P-gp-
mediated MDR reversal activity of the identified compounds, 
an additional series of O-functionalized diethylstilbestrol 
derivatives 26-34, originally prepared as potential PXR 
modulators (Figure 2), were assayed for P-gp inhibition at 
progressive two-fold dilutions from 25 µM. Co-treatment of 
Lucena 1 with 26-30 resulted in enhanced DOX accumulation 
(p < 0.001-0.05), with FIR values ranging from 1.04 to 1.32. 
While 28-30 increased DOX-associated MFI from 3.12 μM (p 
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< 0.01-0.05), 26 and 27 were active from 1.56 μM (p < 0.05), 
with no differences with respect to the same concentrations of 
verapamil and CsA (p > 0.05) (Table 1 and Fig. S2A). Dose-
dependency was observed for 26 (b = 0.0082; p = 0.0106; CI 
95% = 0.0032 to 0.0133), 27 (b = 0.0120; p = 0.0025; CI 95% 
= 0.0071 to 0.0169), 28 (b = 0.0071; p = 0.0109; CI 95% = 
0.0031 to 0.0110), 29 (b = 0.0077; p = 0.0001; CI 95% = 0.0068 
to 0.0087) and 30 (b = 0.0056; p = 0.0009; CI 95% = 0.0009 to 
0.0103). The lack of activity on K562 was confirmed indicating 
that the effect was due to P-gp inhibition (Table S2). 
In addition to DOX accumulation study, a similar assay using 
the dye rhodamine 123 (Rho123), a classic P-gp substrate, was 
further carried out by flow cytometry As observed in Table S3 
and Fig. S2B, compounds 26 and 27 increased the intracellular 
Rho123 as from 50 µM and 12.5 µM, respectively, and were 
significantly different from verapamil and CsA both at 25 and 
12.5 µM, respectively (p < 0.05), but were comparable with 
tamoxifen at the same concentrations (p > 0.05). 
To evaluate the capabilities of the most effective compounds, 
26 and 27, more thoroughly, a multidrug resistance reversal 
assay was carried out (see Supporting Information). The 
different parameters measured by both types of technique 
allowed us to address different aspects related to their 
pharmacological profile to determine the effectiveness of the 
compounds.25 The accumulation assay enables assessment of 
the quantity of substrate accumulated inside the cells resulting 
from inhibition of the efflux, while the multidrug resistant 
reversal assay determines the intracellular activity of a 
cytotoxic drug applied in combination with P-gp modulators 
compared with its individual activity.2 It is worth mentioning 
that Lucena 1 cells displayed 34-fold more resistance to DOX 
toxicity than parental K562 cells, with IC50 values of 48.49 ± 
3.8 and 1.42 ± 0.18 µM, respectively. As expected, 26 and 27 
showed their ability to reverse the P-gp-mediated DOX 
resistance from 1.56 and 0.78 μM, respectively (Table 1 and 
Figure 3), displaying fold reversal (FR) values of 1.30 and 1.16 
(p < 0.05), respectively (Table 1). These results match those 
found in the accumulation assay. To determine whether the 
DOX cytotoxicity restoring effect was specific to P-gp, K562 
cells were treated with 3.12-0.78 μM of 26 or 27. No 
sensitization to DOX on K562 was observed with compound 26 
at 3.12 µM, while 27 was not able to increase DOX toxicity in 
these cells at 1.56 (Table S2, Supporting Information). These 
results showed that both molecules appear as chemosensitizers 
specific to P-gp modulation.
As previously mentioned by Syed et al.,26 P-gp modulators 
submitted to clinical trials present octanol/water partition 
coefficients ranging from 3.64 to 6.81. The partition 
coefficients (CLogP, calculated with ChemDraw Ultra 
software) found for compounds 7-9 and 26-30 are mostly in 
agreement with these values (see Table S4, Supporting 
Information) suggesting that the assayed compounds show a 
similar partition into the lipid bilayer to that observed with the 
anti-P-gp candidates. In addition, the ClogP values obtained are 
higher than 2.92/3.25, the minimum ClogP values established 
for a compound to be considered as an effective P-gp 
inhibitor.27, 28 In the present work, the most potent compounds 
26-30 showed the highest calculated logP values (5.17 to 7.22, 
Table S4) in agreement with  many authors20, 29, 30 who proposed 
that lipophilicity is a key factor for a better inhibition of P-gp. 
The binding mode of 1 was previously described,2 with the 
main contacts occurring with residues S222, A223, K234, F303, 
Y307, Y310, L339, A342 and F343, most of which are amino 
acids from TMH 4, 5 and 6 at the top of the inverted "V" shaped 
by the transmembrane α-helices. All these residues were 
proposed as essential for binding on theoretical and 
experimental bases, as previously stated.2, 15 The inhibitors 7-9 
and 26-30, which were found active by DOX accumulation 
assay and by docking, overlap their binding regions with that of 
the parent compound 1, which in turn overlaps with the 
reference inhibitor tariquidar.2 In particular, compounds 26, 27 
and 30 showed the maximum superposition with tariquidar, 
with 27 being the only compound of the 26-30 series which also 
showed contacts with TMH 3 (T199, F200 and G203). The 
superimposition of 1, 26 and 27 with tariquidar is shown in 
Figure 4. Further details on the binding mode of 26 and 27 are 
available in Supporting Information, Figs. S3-S4. One of the 
most plausible reason behind the difference in activity of 26 and 
27 with respect to DOX and Rho123 accumulation techniques, 
which was also observed in treatments with (±) pinoresinol,2 
concerns to the affinity of each substrate to the binding sites of 
P-gp. This issue may be explained based on the results obtained 
by performing docking studies. The lowest energy docked 
poses of both 26 and 27 bind to the two main sites of DOX, the 
latter with -8.23 and -8.16 kcal/mol binding energies (Fig. S5). 
As shown in Fig S5, also other higher energy conformations of 
26 and 27 (up to 1.2 kcal/mol above the lowest one) overlapped 
these sites as well. However, none of these conformations are 
able to overlap the primary and one of the secondary sites of 
Rho123 (which have similar affinities within 0.3 kcal/mol), as 
illustrated in Fig S6 and Fig. S7. Clearly, neither 26 nor 27 
would be able to inhibit the Rho123 efflux (at least not in the 
same competitive way) as it does with DOX. In sharp contrast, 
the much more flexible and bigger molecule CsA binds in a 
region that occlude the three main Rho123 binding sites 
(binding energies -10.0 to -9.0 kcal/mol), as shown in Figure 
S8. Although smaller than CsA, verapamil still showed a 
similar pattern (Fig. S9, conformations form -9.1 to -8.1 
kcal/mol shown) These differences in the binding preferences 
of both target compounds, of the two model substrates and of 
the reference inhibitors are consistent with the experimental 
observations regarding the preference of 26 and 27, and also of 
tamoxifen, for DOX, whereas CsA and verapamil showed a 
similar behavior with Rho123 or DOX as substrates. 
While compounds 9, 26 and 27, differing only in the length 
of the hydroxyalkoxy side chains (2 to 4 carbon atoms), appear 
as encouraging lead compounds for P-gp inhibition, the 
sulphate ester derivatives 32-34 had no effect. As observed in 
Table 1, the increase in the length of the side chain in 26-27 
with respect to 9 enhanced effectiveness. On the other hand, the 
addition of an O-acetyl group in the side chain (compounds 29-
30) decreased the activity compared to the hydroxy compounds 
26-27. The presence of O-CH3 groups at positions 4 and 4’ of 
compound 8 slightly increased P-gp modulation activity with 
respect to bis-hydroxy compound 7, while the addition of the 2-
hydroxyethyl group in the lateral chain of 7 to give 9 markedly 
increased the MDR-modulating efficiency. 
To further determine the suitability of compounds 26 and 27 
as potential inhibitors of P-gp function, their toxicity on non-
tumoral peripheral blood mononuclear cells (PBMC) was 
evaluated. With an MTT assay,31, 32 26 and 27 showed 34.67 ± 
Page 3 of 7
ACS Paragon Plus Environment






























































0.88 and 41.00 ± 0.58% cytotoxicity at 25 µM, while a complete 
absence of toxicity was observed at 6.25 µM. A compound can 
be considered as cytotoxic when the IC50 values are lower than 
10 µM.33
With these results, the newly identified compounds 26-27, 
appear as promising starting points for the development of 
inhibitors of the P-gp-mediated transport of chemotherapeutic 
drugs such as DOX. The information obtained about the 
structural requirements for activity sheds light on the design of 
further synthetic pinoresinol-related agents able to reverse the 
MDR/P-gp phenotype.
 
Figure 1. Chemical structures of (+)-pinoresinol (1), the PXR 
ligands 2-9 and the ZINC compounds 10-25 showing high 
similarity with 1 by ROCS analysis.
 
Figure 2. Chemical structures of the diethylstilbestrol derivatives: 
26-34.
Figure 3. Dose-response curves for cytotoxicity of doxorubicin 
(DOX) in Lucena 1 and K562 cells with and without compounds 
26 (A) and 27 (B) as determined by the multidrug resistance 
reversal assay. Values are expressed as mean ± SE of at least three 
independent experiments.
Figure 4. (A) Superimposition of the lowest energy poses of the 
inhibitors 1 (highlighted in red), 26 (in yellow), 27 (in violet) and 
the reference inhibitor tariquidar (in green). (B) Binding of the most 
active compound 27 (balls and sticks) showing its main contacts 
(licorice). The cartoon representation of the α-helices is colored 
according to the sequence, from TMH 1 (red) to TMH 12 (blue).
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assays (Figure S2) and poses of binding to P-gp of the most 
active compounds determined by docking (Figure S3-S9).
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ABBREVIATIONS
BCRP, breast cancer resistance protein; CLog P, calculated 
octanol: water partition coefficient; DOX, doxorubicin; FR, 
fold reversal; FIR, fluorescence intensity ratio; MEC, minimum 
effective concentration; MFI, medium fluorescence intensity; 
PBMC, peripheral blood mononuclear cells; P-gp, P-
glycoprotein; PXR, pregnane X receptor; Rho123, rhodamine 
123.
Table 1. Effect of PXR and selected ZINC compounds on P-gp function by doxorubicin accumulation and resistance reversal 








25 12.50 6.25 3.12 1.56 0.78 0.39 0.19 0.098 0.048 0.024
2 0.80 ± 0.02
3 0.72 ± 0.03
4 0.75 ± 0.08
5 1.01 ± 0.03
6 0.90 ± 0.15
7 1.06 ± 0.01* 1.10 ± 0.08 1.04 ± 0.03
8 1.19 ± 0.03* 1.09 ± 0.02** 1.09 ± 0.07
9 1.16 ± 0.08* 1.20 ± 0.04* 1.08 ± 
0.007***
1.01 ± 0.06
21 1.11 ± 0.06
23 0.96 ± 0.01














28 1.21 ± 0.07* 1.15 ± 0.05* 1.12 ± 0.02** 1.07 ± 0.009** 1.03 ± 0.03
29 1.21±0.03*** 1.10 ± 0.02* 1.06 ± 0.02* 1.04 ± 0.01* 1.02 ± 0.01
30 1.18 ± 0.07* 1.10 ± 0.02* 1.09 ± 0.03** 1.08 ± 0.02* 1.01 ± 0.02
31 0.99 ± 0.04
32 1.04 ± 0.05
33 1.03 ± 0.02
34 0.95 ± 0.06
Ver 1.35 ± 
0.009***
1.26 ± 0.03** 1.20 ± 0.06* 1.16 ± 0.03* 1.07 ± 0.03* 1.07 ± 0.07
Page 5 of 7
ACS Paragon Plus Environment






























































Tam 1.13 ± 1.03* 1.07 ± 0.02* 1.05 ± 0.01* 1.01 ± 0.02








Ver: verapamil. Tam: tamoxifen. CsA: cyclosporine A. Fluorescence Intensity Ratio (FIR); analysis of differences between the intracellular 
accumulations of DOX in cells treated with the tested compounds compared to control cells were performed by one-tailed paired t-test. Fold 
Reversal (FR) values were calculated as IC50 of DOX alone/IC50 of DOX in the presence of the tested compounds. Statistical comparisons 
between IC50 of DOX alone or with compound in each treatment were performed by one-tailed paired t-test. Results represent the mean ± SE. 
***p < 0.001, **p < 0.01 and *p < 0.05.
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